This context sparks intriguing speculation regarding the potential correlation between the less discernible therapeutic effects of teriparatide in OI patients and the concurrent elevation in DKK1 levels (Gatti et al. 2013). The gene discussed is DKK1; the disease is osteogenesis imperfecta.